Hwang Lawfirm

More information on Cervical Cancer Vaccine:

Mini-Sentinel is a pilot project to inform the development of an active surveillance system, the Sentinel System, for monitoring the safety of FDA-regulated medical products. FDA’s Center for Biologics Evaluation and Research (CBER) is currently evaluating three different vaccines (RotaTeq, Rotarix and Gardasil) using the Mini-Sentinel system. The inclusion of these vaccines as the subject of a Mini-Sentinel safety evaluation does not mean that a causal association exists between the vaccine and the health outcome being investigated. These evaluations are being conducted to provide better information to help clarify potential safety concerns that have been reported by other surveillance systems and enable FDA to better assess any potential risk.

1. Intussusception after rotavirus vaccination. Intussusception is the most common form of bowel obstruction in infancy and has been closely monitored since the voluntary withdrawal of the first rotavirus vaccine: Rotashield. FDA carefully assessed the risk for intussusception in large clinical trials in more than 60,000 children prior to licensure for both of the currently available rotavirus vaccines (RotaTeq and Rotarix). No increased risk for intussusception was observed in these trials for either vaccine. However, several postmarketing studies from other countries have subsequently suggested a potential increased risk. (FDA is conducting a Mini-Sentinel safety assessment because intussusception is a very rare event and studies thus far have not been large enough to sufficiently evaluate this risk among children in the United States. Mini-Sentinel has the largest general population cohort for vaccine safety surveillance in the United States and FDA is conducting this investigation to better quantify the potential risk of intussusception among US children.
2. Venous thromboembolism (VTE) after human papillomavirus vaccine. Venous thromboembolism is a condition that involves blood clots that form in the deep veins of the body (deep vein thrombosis) or in the lungs (pulmonary embolism). VTE can result from a combination of hereditary and acquired risk factors, including hormonal contraception. FDA approved Gardasil in 2006 based on studies involving more than 21,000 males and females. No increased risk for VTE was identified in these studies. Post licensure surveillance in the Vaccine Safety Datalink identified no safety risks among eight health outcomes which were evaluated, but a non-statistically significant increased rate of VTE after Gardasil was reported.[3] However, all of the confirmed cases of VTE in this study had other risk factors present that might explain their blood clots. FDA is conducting this Mini-Sentinel safety assessment to evaluate VTE with improved control for these other risk factors.

Additional information from the FDA on Cervical Cancer Vaccine:

The results of these two studies will be published and made publicly available upon completion. FDA will evaluate any new safety information from these assessments and will provide updates to healthcare providers and the public to ensure the safe use of vaccines. The Mini-Sentinel safety assessments are part of FDA’s efforts to enhance vaccine safety surveillance, communication, and protection of public health.

http://www.seedol.com

For Continued information on Cervical Cancer Vaccine:

The FDA has recently received inquiries regarding the presence of human papillomavirus (HPV) DNA fragments in Gardasil and is aware that information related to this issue is on the internet. A concern that the presence of these fragments could represent contamination of the vaccine arises from an unpublished report that recombinant HPV L1-specific DNA sequences were present in 13 vials of Gardasil from different lots.

The presence of DNA fragments is expected in Gardasil and not evidence of contamination. Based on the scientific information available to FDA, Gardasil continues to be

safe and effective, and its benefits continue to outweigh its risks.

More (12/20/11) relevant Information for Cervical Cancer Vaccine:

Key Facts:

• Gardasil does contain recombinant HPV L1-specific DNA fragments, but these are not contaminants. DNA encoding the HPV L1 gene is used in the vaccine manufacturing process to produce the virus-like particles that make up the vaccine. The presence of these DNA fragments is expected, is not a risk to vaccine recipients, and is not a safety factor. DNA is the “blueprint” for the majority of living organisms and carries the genetic instructions for how cells function and grow.
• The vaccine manufacturing process is highly regulated under FDA’s current good manufacturing practice requirements, including inspections conducted by FDA of the manufacturing processes and facilities.
• Since the early development of Gardasil, FDA and the manufacturer (Merck and Co., Inc.) have known that after purification of the vaccine, small quantities of residual recombinant HPV L1-specific DNA fragments remain in the vaccine. Gardasil does not contain DNA from other HPV genes or any full-length infectious HPV genomes.
• As it does with all vaccines, FDA continues to monitor the safety of Gardasil. For example, FDA recently evaluated the results of a postmarketing study, which included 189,629 females ages 9 to 26 years, 51% of whom were 9 to 15 years of age to assess the risk for onset of new autoimmune diseases after vaccination with Gardasil. Examples of these types of diseases include juvenile rheumatoid arthritis, lupus, multiple sclerosis, etc. The results of this study showed that there is no elevated risk for onset of new autoimmune disease associated with the use of Gardasil.
• FDA also continually reviews all reports of the Vaccine Adverse Event Reporting System after vaccination with Gardasil, and there is no evidence of unusual clinical patterns or high reporting rates of adverse events, including autoimmune diseases.

One of FDA’s highest priorities is the protection of public health through safe and effective vaccines. As it does with all vaccines, FDA will continue to monitor the safety of Gardasil.

http://www.seedol.com

More information on Gardasil Anaphylaxis:

Mini-Sentinel is a pilot project to inform the development of an active surveillance system, the Sentinel System, for monitoring the safety of FDA-regulated medical products. FDA’s Center for Biologics Evaluation and Research (CBER) is currently evaluating three different vaccines (RotaTeq, Rotarix and Gardasil) using the Mini-Sentinel system. The inclusion of these vaccines as the subject of a Mini-Sentinel safety evaluation does not mean that a causal association exists between the vaccine and the health outcome being investigated. These evaluations are being conducted to provide better information to help clarify potential safety concerns that have been reported by other surveillance systems and enable FDA to better assess any potential risk.

1. Intussusception after rotavirus vaccination. Intussusception is the most common form of bowel obstruction in infancy and has been closely monitored since the voluntary withdrawal of the first rotavirus vaccine: Rotashield. FDA carefully assessed the risk for intussusception in large clinical trials in more than 60,000 children prior to licensure for both of the currently available rotavirus vaccines (RotaTeq and Rotarix). No increased risk for intussusception was observed in these trials for either vaccine. However, several postmarketing studies from other countries have subsequently suggested a potential increased risk. (FDA is conducting a Mini-Sentinel safety assessment because intussusception is a very rare event and studies thus far have not been large enough to sufficiently evaluate this risk among children in the United States. Mini-Sentinel has the largest general population cohort for vaccine safety surveillance in the United States and FDA is conducting this investigation to better quantify the potential risk of intussusception among US children.
2. Venous thromboembolism (VTE) after human papillomavirus vaccine. Venous thromboembolism is a condition that involves blood clots that form in the deep veins of the body (deep vein thrombosis) or in the lungs (pulmonary embolism). VTE can result from a combination of hereditary and acquired risk factors, including hormonal contraception. FDA approved Gardasil in 2006 based on studies involving more than 21,000 males and females. No increased risk for VTE was identified in these studies. Post licensure surveillance in the Vaccine Safety Datalink identified no safety risks among eight health outcomes which were evaluated, but a non-statistically significant increased rate of VTE after Gardasil was reported.[3] However, all of the confirmed cases of VTE in this study had other risk factors present that might explain their blood clots. FDA is conducting this Mini-Sentinel safety assessment to evaluate VTE with improved control for these other risk factors.

Additional information from the FDA on Gardasil Anaphylaxis:

The results of these two studies will be published and made publicly available upon completion. FDA will evaluate any new safety information from these assessments and will provide updates to healthcare providers and the public to ensure the safe use of vaccines. The Mini-Sentinel safety assessments are part of FDA’s efforts to enhance vaccine safety surveillance, communication, and protection of public health.

http://www.seedol.com

For Continued information on Gardasil Anaphylaxis

More (12/20/11) on Gardasil Anaphylaxis:

The FDA has recently received inquiries regarding the presence of human papillomavirus (HPV) DNA fragments in Gardasil and is aware that information related to this issue is on the internet. A concern that the presence of these fragments could represent contamination of the vaccine arises from an unpublished report that recombinant HPV L1-specific DNA sequences were present in 13 vials of Gardasil from different lots.

The presence of DNA fragments is expected in Gardasil and not evidence of contamination. Based on the scientific information available to FDA, Gardasil continues to be

safe and effective, and its benefits continue to outweigh its risks.

More relevant Information for Gardasil Anaphylaxis:

Key Facts:

• Gardasil does contain recombinant HPV L1-specific DNA fragments, but these are not contaminants. DNA encoding the HPV L1 gene is used in the vaccine manufacturing process to produce the virus-like particles that make up the vaccine. The presence of these DNA fragments is expected, is not a risk to vaccine recipients, and is not a safety factor. DNA is the “blueprint” for the majority of living organisms and carries the genetic instructions for how cells function and grow.

• The vaccine manufacturing process is highly regulated under FDA’s current good manufacturing practice requirements, including inspections conducted by FDA of the manufacturing processes and facilities.

• Since the early development of Gardasil, FDA and the manufacturer (Merck and Co., Inc.) have known that after purification of the vaccine, small quantities of residual recombinant HPV L1-specific DNA fragments remain in the vaccine. Gardasil does not contain DNA from other HPV genes or any full-length infectious HPV genomes.

• As it does with all vaccines, FDA continues to monitor the safety of Gardasil. For example, FDA recently evaluated the results of a postmarketing study, which included 189,629 females ages 9 to 26 years, 51% of whom were 9 to 15 years of age to assess the risk for onset of new autoimmune diseases after vaccination with Gardasil. Examples of these types of diseases include juvenile rheumatoid arthritis, lupus, multiple sclerosis, etc. The results of this study showed that there is no elevated risk for onset of new autoimmune disease associated with the use of Gardasil.

• FDA also continually reviews all reports of the Vaccine Adverse Event Reporting System after vaccination with Gardasil, and there is no evidence of unusual clinical patterns or high reporting rates of adverse events, including autoimmune diseases.

One of FDA’s highest priorities is the protection of public health through safe and effective vaccines. As it does with all vaccines, FDA will continue to monitor the safety of Gardasil.

http://www.seedol.com

Actos Attorney 12/15/2011: Ureteral injury may occur when a tumor covers the ureter in the bladder. The ureter may be obscured by a bladder tumor, and the urologist may inadvertently resect it along with the tumor. In general, cutting current to remove a bladder tumor does not usually lead to long lasting problems as compared to cauterization, which is more likely to cause permanent blockage or obstruction of the ureter. If the urologist is working in the area of the ureter, he should avoid cauterization as much as possible. He may ask the anesthetist to inject an intravenous coloring agent which will turn the urine blue and allow visualization of the ureter. If he knows a ureter may be in jeopardy, he may insert a stent (a small plastic tube that traverses the ureter) for several weeks to allow the ureter to heal in an open fashion.

For more information on Actos Attorney follow us on our RSS Feeds.

Our use of the Terms Actos Lawsuit, Actos Cancer is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos Bladder Cancer 12/20/2011: During phase 1 of a cancer trial, the safety of the chemotherapy dose is being determined. During the early part of the trial, a lower dose may be used. The dose is gradually increased to determine the potential for side effects. Individuals entering the trial later may receive higher doses, more potentially serious side effects, and not necessarily more effective therapy. During phase 2, it is determined how often a particular cancer will respond to the chemotherapy at a fixed dose regimen. Lastly, during phase 3, the new drug which appears to be effective is compared to the current accepted chemotherapy for a particular cancer.

For more information on Actos Bladder Cancer follow us on our RSS Feeds.

Our use of the terms Actos and Bladder, Actos Side Effects is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. “Actos” is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos Attorneys 12/15/2011: Many physicians may feel slighted when a patient requests a second opinion. Your urologist may feel somehow you don’t trust his explanations, skill, or judgment. On the other hand, when a new patient faces a difficult or unexpected diagnosis, the urologist may find the request not at all unusual. It is important you explain to your urologist why you feel a second opinion is warranted. Urologists are professionals and will graciously facilitate your request. The experienced urologist comes to realize that despite his best efforts, some patients will seek a second opinion. If a patient is particularly concerned or nervous about a proposed treatment regimen, your urologist may welcome your request. Your urologist should facilitate your second opinion by sending appropriate records and telling you whether or not it is necessary for you to bring X rays or pathology slides with you. Your primary care physician may need to be contacted for the referral if your insurance requires it.

For more information on Actos Attorneys follow us on our RSS Feeds.

Our use of the Terms Actos Lawyers, Actos and Cancer, is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos and Bladder Cancer12/20/2011: When facing the prospects of chemotherapy, it is essential to have an oncologist who can inform you fully of the potential probable effectiveness of the chemotherapy being offered. Just as importantly, the toxicities of the chemotherapy must be fully reviewed. Of course, there are no absolutes when reviewing the potential for success and failure. Each individual’s cancer is unique. Some respond better than others to chemotherapy. General statistics regarding disease regression and remission are available. Absolute numbers for the individual are not.

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

Our use of the Terms Actos Bladder Cancer, Actos Class Action Lawsuit is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos.Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos Lawsuit 11/15/2011- In June of 2011 the United States Food and Drug Administration released information pertaining to the risk of developing bladder cancer associated with taking Actos. Since that time many attorneys have filed an Actos Lawsuit on behalf of those who took Actos and later developed Bladder Cancer. If you were among those that the FDA warning came to late for and you have already developed Bladder Cancer as a result of taking Actos the contact us today. We will arrange a free consultation with an attorney with knowledge of the Actos Lawsuit. Contact us today using the form on this page or by calling our toll free number:

An Actos Lawsuit may be your only way to recover financial damages and protect you and your family. In an Actos Lawsuit you can seek to recover monetary damages for pain and suffering, lost income, losses to your family as a result of your cancer, medical expenses past, present and future as well as other damages you have or will suffer. Although once you have bladder cancer your life may never be the same, an Actos Lawsuit can at least be a path to recover financially for the damage done to you by Actos.

The term Actos Lawsuit is used for descriptive purposes only. The use of the word Actos or Actos Lawsuit does not imply that there is any relationship between Best Legal Source and the Makers of Actos. Best Legal Source is not the maker of Actos. Actos is a registered trademark of its manufacturer, Takeda Pharmaceutical Company Limited, based in Japan.

Our Purpose at Best Legal Source is to help people who have been injured by defective products find the best attorneys for their particular case. The services of Best Legal Source are free to the public. Best Legal Source only works with Attorneys that will take you Actos Lawsuit on a contigency basis. This means if they do not win your Actos Lawsuit, You do not pay. You have everything to gain and nothing to lose by contacting Best Legal Source Today to let us get the process started towards your Actos Lawsuit.

http://www.seedol.com

Actos Bladder Cancer 12/20/2011: Initial side effects experienced by almost all individuals will include nausea and vomiting, diarrhea, mouth ulcers, extreme fatigue, loss of appetite and weight loss, hair loss, and a drop in blood counts. Many of the side effects can be lessened by taking appropriate medication. Long term side effects include low blood count, nerve and kidney damage. Side effects can be severe and potentially life threatening. Death as the result of sepsis from MVAC treatment occurs in approximately 3% of patients. Even if side effects are not severe, chemotherapy may result in the individual rapidly becoming weak and tired, reducing markedly his quality of life. The side effects for the most part are not long lasting with a return to normalcy after chemotherapy has been completed. If you are not tolerating the chemotherapy regimen well, your oncologist can modify the dose, frequency of dosing, or alter the regimen entirely.

For more information on Actos Bladder Cancer follow us on our RSS Feeds.

Our use of the Terms Actos and Cancer, Actos Class Action is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com